First AD

Second AD

Emerging Therapies in the Front-line Setting of Advanced non-clear cell RCC 

Video content above is prompted by the following:

Please review some of the other therapies for the treatment of advanced non-clear cell RCC in the front-line setting:

Phase 2 study (Nivo + Cabo): (Lee CH, et al. ASCO 2023. Abstract 4537)

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Video Series

My Treatment Approach: Translating Evidence to Clinical Practice in Advanced RCC  

A key opinion leader discusses alternative therapies for the first-line treatment of advanced non-clear cell renal cell carcinoma (RCC), focusing on the PAPMET regimen and the results of a relevant Phase 2 clinical study. 

Evolving Treatment Standards in Non-Clear Cell RCC 